Chronic myeloid leukemia (CML) was a fatal disease for almost all patients until the introduction of allogeneic stem cell transplantation (SCT) and of interferon-alfa (IFNα). However, these were of benefit only for a minority of patients.[1][1] The targeted therapies, first imatinib, then the other
No takes yet. Share an insight, caveat, or question.
Baccarani et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: